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plasma microRnA levels in male 
and female children with cystic 
fibrosis
c. Mooney1,2,9, P. J. McKiernan  3,9, R. Raoof1,4, D. C. Henshall1,5, B. Linnane6,7, P. Mcnally6,8, 
A. M. A. Glasgow3* & c. M. Greene3
A gender gap exists in cystic fibrosis (CF). Here we investigate whether plasma microRNA expression 
profiles differ between the sexes in CF children. MicroRNA expression was quantified in paediatric CF 
plasma (n = 12; six females; Age range:1–6; Median Age: 3; 9 p.Phe508del homo- or heterozygotes) 
using TaqMan OpenArray Human miRNA Panels. Principal component analysis indicated differences 
in male versus female miRNA profiles. The miRNA array analysis revealed two miRNAs which were 
significantly increased in the female samples (miR-885-5p; fold change (FC):5.07, adjusted p value: 
0.026 and miR-193a-5p; FC:2.6, adjusted p value: 0.031), although only miR-885-5p was validated as 
increased in females using specific qPCR assay (p < 0.0001). Gene ontology analysis of miR-885-5p 
validated targets identified cell migration, motility and fibrosis as processes potentially affected, with 
RAC1-mediated signalling featuring significantly. There is a significant increase in miR-885-5p in plasma 
of females versus males with CF under six years of age.
Cystic fibrosis (CF) is an autosomal recessive genetic disorder arising from mutations in the cystic fibrosis trans-
membrane conductance regulator (CFTR) gene1. CFTR is a crucial chloride ion channel expressed by epithelial 
cells in the lung and other organs. The consequences of defective CFTR are most severely manifested in the lung, 
where the imbalanced ion homeostasis results in chronic airway inflammation, which leads to a progressive and 
ultimately fatal decline in lung function.
Despite improved therapies and increased life expectancy for both males and females with CF in recent years, 
a gender dichotomy persists whereby females are at a clinical disadvantage e.g. poorer lung function, earlier 
colonisation by chronic mucoid Pseudomonas aeruginosa, greater frequency of exacerbations, and lower median 
survival age2–7. Whether sex differences exist in children with CF remains controversial8,9.
The ability to measure and monitor lung disease in children via a non-invasive method would be highly ben-
eficial for CF clinical care. Molecular biomarkers that are prognostic for lung disease progression could serve, in 
support of clinical examination, to allow earlier and hence more effective intervention strategies. Ideally these 
would be molecules that are stable in body fluids (e.g. plasma), able to be quantified with reliance and accuracy, 
and mechanistically linked to pulmonary infection and/or inflammation.
MicroRNAs are small non-coding RNAs that bind specific target mRNA sequences to inhibit their expression. 
As well as being expressed within cells/tissues, miRNAs are also present extracellularly, and are readily detectable 
in body fluids such as serum and plasma. In contrast to mRNA, miRNAs circulating in plasma are surprisingly 
resistant to RNase degradation due to the fact they are found either packaged inside microvesicles e.g. exosomes, 
or associated with protein/lipid complexes e.g. argonaute 2 or high density lipoprotein10. Although the role of 
circulating miRNAs is not yet fully understood, their major function is thought to be cell-cell communication, for 
example between immune cells10. It has been demonstrated that circulating miRNAs can be taken up by recipient 
cells and subsequently cause changes in target gene expression11,12. Changes in circulating miRNA expression 
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profiles have been found to correlate with specific disease states, e.g. various cancers, highlighting their potential 
use as biomarkers13.
Many miRNAs have been shown to be dysregulated in the CF lung environment, including those with tar-
gets such as CFTR, IL-8, Target of Myb1 (TOM1) and activating transcription factor 6 (ATF6), as reviewed by 
Glasgow et al.14. In this work, we sought to explore the circulating miRNA profile of paediatric CF plasma. Given 
the sex-related differences noted in CF progression, we decided to examine the miRNA profile of samples from 
males versus females with the disease.
Overall, the aims of this study were to measure miRNAs in plasma from children with CF and to corre-
late miRNA profiles or differentially expressed (DE) miRNAs with sex, CFTR genotype, age, lung inflammatory 
markers (neutrophil elastase and interleukin-8), lung infection status and antibiotic treatment.
Results
microRNA expression profiles - Over 100 miRNA can be reliably quantified in paediatric CF 
plasma samples. Analysis of 6 female and 6 male paediatric CF plasma samples was carried out using the 
QuantStudio 12 K Flex Real-Time PCR System. An average of 157 miRNA with a Ct < 25 were detected per sam-
ple before filtering (range: 133–192) (Supp. Fig. 1A). There was no significant difference between the numbers of 
miRNAs identified in the samples from females versus males. After filtering, 118 miRNA remained (Supp. Fig. 1B) 
which compares favourably with other reports of miRNA profiles in serum or plasma in healthy adults15–20. These 
miRNA were cross-checked with miRNAs previously identified in 6 other profiling studies of healthy adults 
(Supp. Table 1). More than half of the miRNA identified are found in at least 4 other studies. Only 5 miRNA were 
not identified in any of these studies (miR-10b-3p, miR-491-5p, miR-625-3p, miR-636 and miR-7a-1-3p).
The 10 most abundant miRNA here are: hsa-miR-16-5p, hsa-miR-19b-3p, hsa-miR-24-3p, hsa-miR-92a-3p, 
hsa-miR-223-3p, hsa-miR-191-5p, hsa-miR-150-5p, hsa-miR-29c-3p, mmu-miR-451a and hsa-miR-484. All 
of these have previously been identified as the most abundant miRNA in other profiling studies of plasma15. 
Potential cell types from which the individual miRNAs could be derived were investigated by comparing to a 
previous report on miRNA expression profiles in a range of cell types, as shown in Supp. Table 221.
Correlations between altered miRNA and sex or genotype. Next, a principal component analysis 
(PCA) was performed and the first two principal components (PC1 and PC2) were plotted. This showed some 
separation of the male and female samples (Fig. 1A). However, this does not fully explain the obvious separation 
of the samples into two clusters. Despite investigating this in depth, there is no clear explanation for this cluster-
ing based on batch effects, age, CFTR genotype, bronchoalveolar lavage (BAL) cell counts, BAL IL-8 or neutro-
phil elastase levels, infection status or antibiotic treatment. However, ‘Sex’ has the highest correlation with PC1 
(r = 0.39) and ‘Genotype’ with PC2 (r = −0.53; Fig. 1B). Upon further investigation, it was apparent there were 
four miRNAs that correlated highly with PC1: miR-151-3p (r = −0.98), miR-29c-3p (r = −0.74), miR-139-5p 
(r = 0.72) and miR-132-3p (r = 0.76). Two of these (miR-151-3p and miR-29c-3p) are expressed at very high 
levels in a number of samples (e.g. miR-151-3p Ct < 10; Supp. Table 3) and drive the data into the two clusters, as 
demonstrated in Supp. Fig. 2A–D, where hypothetical removal of these two miRNAs removes the clustering of 
the samples in the PCA.
miR-885-5p is elevated in plasma from girls versus boys under the age of six with CF. The 
TaqMan OpenArray detected two significantly differentially regulated microRNAs in male versus female samples 
Figure 1. (A) Principal component analysis (PCA) was performed on samples after removal of lowly expressed 
miRNAs (Ct >25) and normalisation of Ct values. (B) Correlation plots showing the correlation between sex, 
genotype (GT), age, BAL Total cell count (BAL), neutrophil elastase levels (NEL), IL-8 concentration (IL-8), 
Haemophilus spp. (Haem), Escherichia spp. (Esch), Staphyloccus spp. (Staph), antibiotic treatment (Antib), PC1 
and PC2. The size of the circles is proportional to the strength of the correlation and the colour represents the 
direction i.e. a large dark blue circle represents a strong positive correlation and a large dark red circle represents 
a strong negative correlation.
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(Fig. 2A,B); miR-885-5p and miR-193a-5p. Validation for miR-885-5p and miR-193a-5p was performed by indi-
vidual RT-qPCR on the original 12 CF plasma samples. Whilst miR-193a-5p failed to validate (data not shown), 
levels of miR-885-5p were confirmed to be significantly elevated in the female versus male CF plasma (Fig. 2C, 
p < 0.0001).
Interestingly, analysis of the p.Phe508del homozygous males versus females (n = 4 per group) revealed signif-
icantly decreased levels of miR-17 and increased miR-199a-3p in the female samples (Fig. 2D–E).
Pathway links between plasma miR-885-5p and pathomechanisms in cystic fibrosis. In silico 
analysis of validated targets of miR-885-5p was carried out to gain insight into whether this miRNA may have a 
pathological role in CF lung disease or the CF gender gap. Experimentally validated targets of miR-885-5p were 
retrieved from miRTarBase, focusing only on human targets with supporting experimental evidence from more 
than one publication. Figure 3A shows the nine validated targets of miR-885-5p retrieved from miRTarBase. 
These were uploaded to Enrichr in order to explore gene ontology biological processes and pathway involvement. 
The significantly associated gene ontology terms (adjusted p-value <0.05) obtained were imported to REGIVO, 
clustered based on their relatedness, and any redundancy removed. Visualization of these results showed that 
the largest clusters were formed from the gene ontology biological processes involving tyrosine kinase signalling 
and cell migration/motility (Fig. 3B). Significantly enriched (adjusted p-value <0.001) Reactome, NCI Nature 
and BioCarta pathways for targets of miR-885-5p obtained from Enrichr are shown in Supp. Tables 4–6. The 
vast majority of significantly associated gene ontology terms and enriched pathways were associated with RAC1, 
with the other eight miR-885-5p target genes featuring minimally. A number of potential CF-related pathways 
were identified including actin cytoskeleton organization, cell migration/motility, microtubule polymerization, 
Roundabout receptor (Robo) signaling, hepatocyte growth factor (HFG) receptor signaling and fibrosis-related 
pathways. Pathways of interest are marked by grey shading in Supp. Tables 4–6 and summarized visually in 
Fig. 3C.
Discussion
We, and others, have previously shown that numerous miRNAs are differentially expressed in the lungs of CF 
adults14,22,23. The aim of this study was to investigate whether plasma microRNA expression profiles differ between 
the sexes in children with CF. The main finding of our study is that miR-885-5p is increased in the plasma of 
female versus male children with CF under the age of six, implicating RAC1-mediated processes as potentially 
differing between the sexes. To our knowledge, this is the first report of differences in miR-885-5p plasma levels 
in the context of a lung pathology, however there are previous reports of increased circulating blood levels of miR-
885-5p associated with a range of liver pathologies24. Extracellular miRNAs can be present in a variety of body 
Figure 2. (A,B) Boxplots showing the distribution of normalised Ct for the two miRNAs found significantly 
differentially expressed between females and males in the TaqMan OpenArray: (A) miR-193a-5p and (B) miR-
885-5p. (C) Validation of differential expression of miR-885-5p by qPCR, p < 0.0001. (D,E) Box plots showing 
the distribution of normalised Ct for the two miRNAs found differentially expressed between p.Phe508del 
homozygous females and males in the TaqMan OpenArray: (D) miR-17 and (E) miR-199a-3p.
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fluids due to either active or passive processes and ideally can represent a unique molecular barcode with diag-
nostic value. The source of the plasma miR-885-5p could not be determined, notwithstanding that the miRNA 
expression profiles of 18 different cell types were taken into consideration, due to the fact that miR-885-5p does 
not feature in the top 100 miRNAs expressed in the cell types examined21.
Indeed miRNAs have been proposed to hold potential as biomarkers for CF disease progression25, as exem-
plified in a recent study by Krause et al. which reported that levels of the Mirc1/Mir17–92 cluster in CF sputum 
correlated with pulmonary exacerbations, lung function and age26. The samples used in that study were predom-
inantly from adults, and correlations with gender were not explored. A previous study by Cook et al. on circulat-
ing miRNAs in serum found altered expression of three miRNAs between CF patients with liver disease, those 
without liver disease, and non-CF paediatric controls, as well as a panel of six miRNAs that could distinguish 
between progressive states of liver fibrosis27. Additionally, a recent profiling study comparing plasma miRNAs 
in CF versus non-CF controls validated the increased expression of miR-486-5p, let-7b and miR-103a-3p in CF 
plasma28. However, neither the serum nor plasma study examined differences between male and female sam-
ples. Given that sex differences play a role in CF lung disease progression, in this pilot study the plasma miRNA 
expression profile of six male versus six female children with CF was compared as a first step towards identifying 
candidate biomarkers of clinical status that may represent the CF gender gap and/or ultimately be useful for guid-
ing earlier therapeutic interventions. Having identified miR-885-5p as a candidate miRNA that may differentiate 
male and female CF plasma samples, the biological significance of this alteration needs to be explored in future 
mechanistic studies. However, based on robust bioinformatic analysis it is possible to speculate on what pathways 
may be affected.
miR-885-5p has a number of experimentally validated targets (Fig. 3A) and the combined significant gene 
ontology terms that were retrieved following bioinformatic analysis of these targets pointed to numerous cell 
processes that are of potential relevance to CF. The majority of the pathways featured RAC1. RAC1 is a member of 
the Rho family of small (~21 kDa) signalling proteins. Rho GTPases are known to regulate CFTR trafficking and 
expression29, as well as numerous aspects of actin dynamics including actin filament polymerisation. Hepatocyte 
growth factor (HGF) also featured, which is involved in lung repair by blocking apoptosis in epithelial cells and 
preventing fibrosis30. Together HGF and RAC1 enhance the rescue of CFTR to the cell surface by pharmacological 
Figure 3. (A) Table showing experimentally validated targets of miR-885-5p, as retrieved from miRTarBase. 
Only targets with evidence from more than one publication are listed. (B) Removal of GO term redundancy and 
semantic visualisation of the significantly associated GO biological processes (adjusted p value < 0.05) using 
REVIGO. The scatterplot shows the cluster representatives (after redundancy reduction) in a two-dimensional 
space derived by applying multidimensional scaling to a matrix of the GO terms’ semantic similarities (the axes 
have no intrinsic meaning). Bubble colour indicates the log10 (adjusted p value); size indicates the frequency 
of the GO Biological Process terms in the underlying UniProt database (bubbles of more general terms are 
larger). (C) Schematic summarising RAC1 related pathways by which miR-885-5p may potentially influence CF 
pathogenesis (dashed lined indicates ‘possible’).
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correctors31. Importantly, therefore, the observation that miR-885-5p is elevated in female CF plasma may have 
implications for male versus female responses to CFTR modulator therapy. Lumacaftor is a CFTR corrector that 
promotes the proper folding and maturation of Phe508del-CFTR whereas Ivacaftor enhances the channel open 
probability of the mutant CFTR. Lumacaftor alone does not produce changes in CF lung function but does so 
when applied in combination with Ivacaftor. The underlying mechanism of combined action of these CFTR mod-
ulators is to increase Phe508del-CFTR membrane expression to stimulate transepithelial Cl- secretion. Moniz 
et al. reported that restoration of Phe508del-CFTR plasma membrane localization by CFTR correctors can be 
dramatically improved through stimulation of signalling by RAC1 via HGF31. Protein quality control mechanisms 
remove improperly folded proteins from the plasma membrane and can limit the efficacy of some CFTR modu-
lator drugs, such as Lumacaftor. Activation of RAC1 promotes an interaction between ezrin and NHERF1, and 
it has been reported that co-exposure of airway cells to RAC1 can triple the efficacy of Lumacaftor32. Thus, acute 
co-treatment with HGF can significantly enhance the chemical correction of Phe508del-CFTR via induction 
of RAC1. Interestingly, prolonged, 15-day HGF treatment also significantly improves the functional rescue of 
Phe508del-CFTR by Ivacaftor/Lumacaftor in polarized bronchial epithelial monolayers33.
Other common themes among the pathway terms were cell migration/motility, inflammation and fibrosis, 
each of which are strongly implicated in neutrophil recruitment to the lung and damage to pulmonary tissue.
Interestingly, when the p.Phe508del homozygous individuals were analysed separately (n = 4 per group), 
significantly decreased levels of miR-17 and increased levels of miR-199a-3p were evident in the female sam-
ples, suggesting that genotype-specific effects may indeed exist. miR-17 targets IL-8, and we previously reported 
decreased levels of miR-17 in CF bronchial brushings34, and later suggested how manipulation of miR-17 in CF 
bronchial epithelial cells could have therapeutic benefit35. A recent report by Bardin et al. pointed to a role for 
miR-199a-3p in the chronic inflammation of the CF airway36. miR-199a-3p was found downregulated in primary 
air-liquid interface cultures and bronchial explants from CF versus non-CF controls, and was demonstrated to 
regulate the expression of inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β), a signalling interme-
diary of the NF-κB pathway36. No significant difference in expression of miR-199a-3p was found in CF versus 
non-CF plasma, however the authors have not stated the sex of the patients in each group36. Larger cohort studies 
could confirm whether these miRNAs represent useful clinical biomarkers.
As part of the miRNA profile analysis, filtering conditions were used that removed a miRNA if it had a Ct 
cycle >25 in more than 80% of samples. PCA analysis of the 118 remaining miRNAs showed a separation of 
the samples into two distinct clusters. Whilst PC1 showed some correlation with sex and genotype, and PC2 
was strongly correlated with genotype, the clustering of the samples was not wholly attributable to any of the 
subject characteristics recorded here i.e. sex, genotype, lung inflammatory parameters, lung infection status or 
antibiotic treatment. Instead, the separation appeared to be driven by very high expression levels of two miRNAs: 
miR-151-3p and miR-29c-3p, although these two miRNAs were not differentially expressed between the sexes. 
Functionally, miR-151-3p has been shown to affect innate immune signalling by targeting signal transducer and 
activator of transcription 3 (STAT3) and thereby inhibiting IL-6 production in macrophages37. It can also affect 
cell migration by enhancing E-cadherin expression via the transcription factor Twist-related protein 1 (TWIST1). 
miR-29c-3p has an important role in the inhibition of apoptosis via targeting of forkhead box O3a (FOXO3A), 
thereby promoting epithelial cell renewal and preventing pulmonary fibrosis38. It also regulates cell migration by 
targeting cell migration-inducing and hyaluronan-binding protein (CEMIP) and the Wnt/β-catenin and epider-
mal growth factor receptor (EGFR) signalling pathways39. Although highly expressed in CF plasma, interestingly, 
miR-151-3p and miR-29c-3p are downregulated in CF versus non-CF adult bronchial brushings22. More in depth 
analysis of the functional roles of these miRNAs in CF is warranted.
This was a pilot study, not without limitations, investigating male versus female differences in plasma miRNA 
expression patterns. The sample groups are small and there is a need to follow up in due course with validation of 
the findings in a larger sized study. These results warrant a longitudinal study evaluating miRNA expression over 
time in the same individuals, comparing males versus females, with more clinical outcomes and an expanded 
cohort in order to fully determine the usefulness of miR-885-5p as a clinical biomarker for monitoring CF disease 
progression or response to CFTR modulator treatment. We are also interested in examining any potential changes 
to the miRNA expression profile with the onset of puberty. Our current findings in these paediatric samples are 
unlikely to be explained by the hormonal influences that are blamed for much of the gender gap in older females, 
and are thus of even greater interest. Although in depth in silico analyses was performed, mechanistic studies 
were beyond the scope of the current work but are warranted in the future in order to test if increased levels of 
miR-885-5p in female CF plasma are representative of a functional difference, and therefore potentially useful 
in monitoring the course of the disease and the CF gender gap. In conclusion, we have recorded significantly 
elevated levels of miR-885-5p in the plasma of female versus male children with CF, and the data suggest RAC1 
may be a key molecule that functions via numerous different pathways, including cell migration and fibrosis, to 
aggravate CF pathogenesis in females.
Methods
Study cohort. Twelve children with CF were recruited (six males; Age range:1–6; Median Age: 3; 8 (66.7%) 
Phe508del homozygote, 1 (8.3%) Phe508del heterozygote, 2 (16.7%) G551D homozygote, 1 (8.3%) other) 
(Table 1). Plasma was recovered by blood draw. Bronchoalveolar lavage was performed40; total BAL cell counts 
were recorded and BAL fluid IL-8 and neutrophil elastase levels were measured by ELISA.
All study participants were recruited as approved by the Ethics Medical Research Committee of Our Lady’s 
Children’s Hospital Crumlin (GEN/228/11). All acquisition, processing and storage of plasma samples was car-
ried out in accordance with the national guidelines and regulations. Written informed consent was provided by 
a parent or guardian.
6Scientific RepoRtS |         (2020) 10:1141  | https://doi.org/10.1038/s41598-020-57964-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
miRNA profiling. Plasma was obtained from the study participants. Since hemolysis of blood samples can 
alter the miRNA profile of plasma, only non-hemolysed samples were used in the study. Absorbance at 414 nm 
was measured by spectrophotometry and samples above 0.25 were excluded due to hemolysis as previously 
described15. RNA was isolated using the miRNeasy Serum/Plasma kit (Qiagen) and reverse transcribed using 
pre-defined Megaplex™ pool RT-primers. Pre-amplifications were performed and miRNA expression was quan-
tified using TaqMan OpenArray Human miRNA Panels in the QuantStudio™ 12 K Flex Real-Time PCR system, 
allowing for 754 miRNAs to be quantified per sample.
openarray data and statistical analysis. OpenArray profiling data (Gene Expression Omnibus sub-
mission GSE132106) were first analysed using the ExpressionSuite Software (Life Technologies). To ensure good 
quality detection and to avoid false-positives, if the quality control flags “AmpScore” or “CqConf ” were <1.24 
or <0.8 respectively then the Ct score was set to “Undetermined”. AmpScore and Cq Confidence were pro-
vided by ExpressionSuite software. Cut-off thresholds were set in consultation with technical experts at Applied 
Biosystems.
All further analyses were performed in R/Bioconductor41. The data was filtered thereby removing a miRNA if 
it was “Undetermined” or had a cycle threshold (Ct) score >25 in more than 80% of samples. Note that Ct values 
are inversely related to expression level i.e. a lower Ct value corresponds to higher expression. Missing data points 
were imputed (Bioconductor package “Non-detects”42) and the data was normalised to the geometric mean (GM) 
as implemented in Bioconductor package “HTqPCR”43. Using these criteria, 636 miRNAs were filtered out, leav-
ing 118 miRNAs in the final data analysis (Fig. 1A,B).
Differential expression analysis was performed by applying a Student’s t-test to the normalized Ct values 
between the two conditions and the p-values were adjusted for multiple testing by controlling the false discov-
ery rate (FDR) according to the method of Benjamini and Hochberg44. A miRNA was considered to be differ-
entially expressed if the adjusted p-value was ≤0.05. Fold changes (FC) were calculated as FC = 2−∆Ct, where 
∆Ct = CtmiRNA − GM.
The miRNAmeConverter Bioconductor package45 was used to convert miRNA names from the miRBase V14 
nomenclature, as used on the OpenArray platform, to miRBase V21 nomenclature, as used in the Results and 
Discussion sections.
miRNA TaqMan assays. Validation of OpenArray findings was performed using qRT-PCR based TaqMan 
miRNA assays as recommended by the manufacturer. Mature miRNA expression was measured on a LightCycler® 
480. cDNA was thawed on ice and diluted immediately before PCR by adding 200 µl RNase-free H2O to the 20 µl 
cDNA sample. Using the 2 × QuantiTect TaqMan PCR Master Mix, reagents for a 25 µl reaction, including diluted 
cDNA were mixed and added to each well. Data analysis was performed on Ct values and relative expression was 
calculated using the 2−ΔΔCt method using U6 small RNA controls. Data were analysed with GraphPad Prism 4.0 
software package (GraphPad Software, San Diego, CA). Specific analyses that were performed are described for 
each figure. Differences were considered significant at p < 0.05.
Pathway analyses and bioinformatics. Experimentally validated microRNA targets for miRNA were 
retrieved from miRTarBase46. Only human targets with evidence from more than one publication were retained. 
The genes identified were uploaded to Enrichr (gene set enrichment analysis web server)47 and the gene ontology 
biological processes, molecular function and pathway involvement of the targets were explored. The significantly 
associated gene ontology terms (adjusted p-value <0.05) were imported to REVIGO where they were clustered 
based on their relatedness and any redundancy was removed48. Significantly enriched Reactome, NCI Nature 
and BioCarta pathways with adjusted p-value <0.001 were exported from Enrichr to Excel and examined for 
CF-related processes.
Sex CFTR Genotype
Age 
(yr)
BAL cell no. 
(x106/ml) NE levels
IL-8 (pg/
ml)
Streptococcus 
spp.
Haemophilus 
spp.
Escherichia 
spp.
Staphylococcus 
spp.
Moraxella 
spp.
Antibiotic 
Treatment
F p.Phe508del/ p.Phe508del 1 1.2 32.46 185.45 − − − − − No
F p.Phe508del/ p.Phe508del 6 74.7 0.00 192.10 + − − + − No
F G551D/G551D 3 1.1 54.52 276.27 − + − − − No
F G551D/G551D 4 4.2 0.00 1673.19 − − − − − No
F p.Phe508del/ p.Phe508del 1 3.1 0.00 1716.03 - − − − − Yes
F p.Phe508del/ p.Phe508del 2 41 0.00 1745.38 − − − − − No
M p.Phe508del/ p.Phe508del 3 2.7 13454.38 336.85 + − − − Yes
M p.Phe508del/ p.Phe508del 4 86 0.00 841.81 − − − − − No
M p.Phe508del/c.2988+1 G > A 2 0.27 0.00 841.81 − + + Yes
M C489+2 G > T/c.1558 G > T 1 7.5 0.00 109.08 + − − Yes
M p.Phe508del/ p.Phe508del 3 15 0.00 512.74 + − − − + Yes
M p.Phe508del/ p.Phe508del 3 55.1 227.71 1162.45 + − − Yes
Table 1. Patient characteristics of the study cohort.
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Data availability
The dataset generated and analysed from the miRNA profiling is publically available at Gene Expression Omnibus 
(GEO), submission number GSE132106.
Received: 30 August 2019; Accepted: 21 December 2019;
Published: xx xx xxxx
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